Scientific Publications
Filter:
Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study
Aziz, A.A., Khanani, A.M., Khan, H. et al. Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study. Eye (2024). https://doi.org/10.1038/s41433...
Clinical Use of Home OCT Data to Manage Neovascular Age-Related Macular Degeneration
Heier JS, Liu Y, Holekamp NM, Ali MH, Astafurov K, Blinder KJ, Busquets MA, Chica MA, Elman MJ, Fein JG, Hahn P, London N, Margolis T, Modi YS, Rachitskaya A, Schneider EW, Stoller GL, Wang JC, Shah AR. Clinical Use of Home OCT Data to Manage Neovascular Age-Related Macular Degeneration. J Vitreoretin Dis. 2024 Dec 7:24741264241302858. doi: 10.1177/24741264241302858. Epub ahead of print. PMID: 39654701; PMCID: PMC11625398. https://pubmed.ncbi.nlm.nih.go...
Artificial intelligence in assessing progression of age-related macular degeneration
Frank-Publig, S., Birner, K., Riedl, S. et al. Artificial intelligence in assessing progression of age-related macular degeneration. Eye (2024). https://doi.org/10.1038/s41433...
Home OCT and Sustained Delivery Approaches, a Perfect Marriage
Holekamp, Nancy M.; N1 - DOI: 10.1016/j.ajo.2024.10.031 | American Journal of Ophthalmology. https://www.ajo.com/article/S0002-9394(24)00512-9/abstract
Prospective Trial of Home OCT Guided Management of Treatment Experienced nAMD Patients
Holekamp, Nancy M. MD; de Beus, Anthony M.; Clark, W. Lloyd; Heier, Jeffrey S. MD. Prospective trial of Home OCT guided management of treatment experienced nAMD patients. Retina The Journal of Retinal and Vitreous Diseases: 10.1097/IAE.0000000000004167, May 22, 2024. | DOI: 10.1097/IAE.0000000000004167 https://journals.lww.com/retin...
SCANLY Home OCT FDA Intended Use
SCANLY Home OCT has not been approved by FDA for use other than described in the following Intend Use: The Notal Vision Home Optical Coherence Tomography (OCT) System is an Artificial Intelligence (AI)-based Home Use device indicated for visualization of intraretinal and subretinal hypo-reflective spaces in a 10 by 10-degrees area centered on the point of fixation of eyes diagnosed with neovascular age-related macular degeneration (NV-AMD). In addition, it provides segmentation and an estimation of the volume of hypo-reflective spaces. The Notal Home OCT device is intended for imaging at home between regularly scheduled clinic assessments and not intended to be used to make treatment decisions or replace standard-of care regularly scheduled examinations and clinical testing as needed, including in-office imaging and assessments for changes in vision, by an ophthalmologist.
See also Warnings and Precautions.
ForeseeHome FDA Intended Use
ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
